In addition to existing antibodies and biologics in its portfolio, CCAB will provide access to its platform technology and infrastructure in working with partners to provide ‘de-novo’ solutions for their unique or proprietary research and drug discover programs, through various business and licensing models. These models include access to our antibody pipeline, binding sequences and proprietary technologies for the development of engineered products including:
- Antibody Drug Conjugate (ADC) solutions.
- Bi Specific or Multi Specific antibodies
- Bispecific T Cell Engager Technologies (BiTEs)
- Chimeric antigen receptor technologies (CAR-T cell therapy)
Reagents: Through CCAB’s selection process, antibodies that are not identified for therapeutic development, but exhibit competitive properties for use within flow cytometry, IHC, ELISA, Western or other assay systems are tested and optimized for reagent use. CCAB has a growing portfolio of antibody reagents, tools and technologies that are available for licensing as reagents.